Media Release
Zofingen, November 12, 2024

Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), reached another milestone on its path to strengthen its offering in the biologics space, particularly in the fast-growing cell and gene therapy market. DINAMIQS, which became part of the Siegfried group in May 2023, inaugurated its cutting-edge laboratories in Zurich's Bio-Technopark, Switzerland.

The fully equipped lab features high-end pilot-scale equipment, enabling DINAMIQS to provide clinical viral vector development, analytical and manufacturing services to meet the growing needs of the cell and gene therapy market. It is an integral part of DINAMIQS' 2,500m² cGMP manufacturing facility for viral vectors, which is currently under construction and set to be operational by the end of 2025. This facility will host up to 1,000L production capacity for the production of viral vectors for R&D, clinical trials and commercial use under one roof.

Marcel Imwinkelried, Chief Executive Officer Siegfried: “Aligned with Siegfried's strategy EVOLVE⁺, the new lab facility marks a key milestone in DINAMIQS' journey to becoming the leading CDMO in the cell and gene therapy space. The team is making significant strides toward bringing DINAMIQS' capabilities to commercial scale."

Martin Kessler, Chief Executive Officer DINAMIQS: "We know about the importance of leading process development and analytics for the success of viral vector projects. This is why we have expanded our Swiss labs significantly. From the optimization of genomes to GMP scale-up, our clients now get everything out of one hand."

• DINAMIQS, a Siegfried company specialized in viral vector design and manufacturing, inaugurated its new state-of-the-art R&D laboratories in Zurich's Bio-Technopark
• The new laboratory capacities house leading technologies in the field of viral vector process development and manufacturing
• With this expansion, Siegfried is on track to strengthen its position in the fast-growing cell and gene therapy market

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2023, the company achieved sales of CHF 1.272 billion and employed on 31.12.2023 more than 3700 people at twelve sites on three continents. Siegfried Holding AG is publicly listed on the SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services. 

About DINAMIQS

DINAMIQS, a Siegfried company, is a science-driven Contract Development and Manufacturing Organization (CDMO) offering end-to-end viral vector manufacturing solutions. DINAMIQS offers a comprehensive and customized range of manufacturing services, process development, quality control and analytics solutions for genetic medicine companies. It is located in Schlieren-Zurich Bio-Technopark in Switzerland.

Cautionary Statements Regarding Forward-Looking Statements

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.

expect more
 

Siegfried AG
Untere Brühlstrasse 4
4800 Zofingen, Switzerland

1